FACTOR CERTIFICATE - MODERNA | Real-time Euronext Paris 08:13:58 16/05/2024 BST | ||
| 0.0967 EUR | -8.51% |
|
| Current month | -84.20% | ||
| 1 month | -89.38% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 16/05/24 | 0.0967 | -8.51% |
| 15/05/24 | 0.1057 | +7.09% |
| 14/05/24 | 0.0987 | -25.51% |
| 13/05/24 | 0.1325 | -22.06% |
| 10/05/24 | 0.17 | +24.72% |
Real-time Euronext Paris
Last update May 16, 2024 at 08:13 am
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| 2662S | |
| ISIN | DE000SU5XKV9 |
| Date issued | 19/12/2023 |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 51.2 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 51.7 € |
|---|---|
| Lowest since issue | 0.0949 € |
| Spread | 0.0019 € |
| Spread % | 1.78% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
129.1
USD
Average target price
138.5
USD
Spread / Average Target
+7.32%
- Stock Market
- Certificates
- 2662S Certificat
